肾上腺素β受体阻滞药治疗婴幼儿血管瘤的研究进展  

Advance of adrenergic beta-blockers in treating infantile hemangiomas

作　　者：李健和[1] 胡焰[2] 王霞[2] 赵子影[2] 彭六保[1] 刘新义[1] 易利丹[1] 

机构地区：[1]中南大学湘雅二医院药学部,湖南长沙410011 [2]中南大学药学院,湖南长沙410013

出　　处：《中国新药与临床杂志》2013年第10期780-784,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：越来越多的临床研究表明,口服或局部给予肾上腺素β受体阻滞药治疗婴幼儿血管瘤起效迅速,疗效良好,不良反应小。外用噻吗洛尔、口服阿替洛尔或醋丁洛尔较口服普萘洛尔安全性更好。然而,由于阿替洛尔、醋丁洛尔及噻吗洛尔治疗血管瘤的研究病例数较少,是否与普萘洛尔具有等同或更好的疗效及耐受性还有待进一步研究。An increasing number of clinical studies showed that adrenergic beta- blockers had rapid effects, good efficacy and fewer adverse reactions in treating infantile hemangiomas by oral or local administration. Timolol for external use, atenolol or acebutolol by oral administration are securer than propranolol. However, it should be further research to determine whether the efficacy and tolerability of atenolol, acebutolol and timolol are equivalent to or better than propranolol because of its limited cases in treating hemangioma.

关 键 词：肾上腺素能Β受体拮抗剂 血管瘤 儿童 

分 类 号：R982[医药卫生—药品]